Parvovirus B19 infections in state of Rio de Janeiro, Brasil: 526 sera analyzed by IgM-enzyme-linked immunosorbent assay and polymerase chain reaction

Mendonça, Marcos César Lima de; Ribeiro, Samantha; Couceiro, J. N. S. S.; Hubinger, M. G. Von

doi:10.1590/s0074-02762005000800005

Cited by 7 publications

(7 citation statements)

References 29 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies were conducted to determine the etiology of fever and rash illness, mainly in countries approaching or having achieved measles and rubella elimination . The Americas achieved elimination in 2015/2016 and our study found no evidence of measles and rubella in Cuba since none of the nearly 300 samples investigated were IgM positive for these diseases.…”

Section: Introductioncontrasting

confidence: 42%

See 1 more Smart Citation

Identification of human parvovirus B19 among measles and rubella suspected patients from Cuba

Ribas

Tejero

Cordero

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

Between September 2014 and December 2015, 298 sera from rash and fever patients from all over Cuba were investigated for specific IgM antibodies against measles, rubella, dengue, human parvovirus B19 (B19V) and human herpesvirus 6 (HHV6) using a commercial enzyme-linked immunosorbent assay kits. B19V IgM positive and equivocal samples were investigated by a polymerase chain reaction and genotyping. No measles, rubella or dengue cases were detected. HHV6-IgM antibodies were confirmed in 5.7% and B19V-IgM antibodies in 10.7% of the patients. A total of 31.3% of the B19V cases were between 5 and 9 years old and 34.4% were 20 years and older. The only B19V sequence obtained belonged to genotype 1a. Diagnosis was established for only 16% of the rash and fever patients, suggesting that other diseases such as Zika or Chikungunya may play a role. K E Y W O R D SCuba, human parvovirus B19, rash-fever

show abstract

Section: Introductioncontrasting

confidence: 42%

“…In the present study, positive cases were found in all age groups, but especially among children between 5 and 9 years and in adults above the age of 19 years. While reports about B19V infection in school children are common, outbreaks in adults like the one reported in the nineties from Cuba are rare, but often involve more severe sequel.…”

Section: Introductionmentioning

confidence: 97%

Identification of human parvovirus B19 among measles and rubella suspected patients from Cuba

Ribas

Tejero

Cordero

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Serological determinations confirmed that B19V was a significant local aetiological agent of this clinical entity, accounting for 14·9% of all the studied cases and 39·1% in the epidemic year (Table 2). The difference found in our population between the global percentage of IgM+ patients and the percentage of IgM+ patients in the epidemic year reflects the range of B19V-specific IgM detection in patients with rash diseases published in the region, which goes from as low as 3·3% up to 31·8%, with frequent recorded values of 12–13% [8, 9, 12, 13, 20, 21].…”

Section: Discussionmentioning

confidence: 66%

Infection and immunity for human parvovirus B19 in patients with febrile exanthema

et al. 2011

View full text Add to dashboard Cite

The contribution of parvovirus B19 (B19V) as a causative agent of febrile exanthema (FE) in Cordoba, Argentina, was analysed by detection of viral DNA, and specific IgM and IgG. Serum from 141 patients with FE who were negative for measles and rubella, collected during 2005-2009, plus serum from 31 healthy individuals, were assayed. B19V was the aetiological agent in 14·9% of all FE cases, and in 39·1% in an epidemic year (2007). B19V DNA was detected in 47·6% of IgM-positive FE patients, 30·2% of IgM-negative/IgG-positive FE patients, and 9·7% of healthy controls, indicating B19V long-term infection in ~10% of immunocompetent individuals. Persistent B19V DNA was significantly more frequent in children than adults and in males than females. All patients with acute B19V infection had rash and fever, 85·7% had adenopathy, and only 14·3% had arthropathy. This is the first follow-up study of markers of infection and immunity for B19V infection in Argentina.

show abstract

“…Previously, Mendonç a et al have analyzed 526 sera collected from symptomatic patients (exanthema, fever, adenomegaly, and arthralgia) from Brazil, by IgMenzyme-linked immunosorbent assay and polymerase chain reaction, and reported 8.8% simultaneous positivity by the two methods in such symptomatic patients. 20 Vallerini et al reported single sample positivity for B19 DNA after testing 100 blood donor samples by nested PCR. 21 The incidence of B19 DNA positivity in Germany and Austria has been found to range from 12.7 to 261.5 per 100,000 blood donations depending on virus loads equal to or above 10 5 and below 10 5 IU per mL, respectively.…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of human parvovirus B19 in healthy blood donors

Kumar

Gupta²,

Sen³

et al. 2013

Medical Journal Armed Forces India

View full text Add to dashboard Cite

a b s t r a c tBackground: Human parvovirus B19 is an emerging transfusion transmitted infection.Although parvovirus B19 infection is connected with severe complications in some recipients, donor screening is not yet mandatory. To reduce the risk of contamination, plasma-pool screening and exclusion of highly viraemic donations are recommended. In this study the prevalence of parvovirus B19 in healthy blood donors was detected by ELISA.Methods: A total of 1633 samples were screened for IgM and IgG antibodies against parvovirus B19 by ELISA. The initial 540 samples were screened for both IgM and IgG class antibodies and remaining 1093 samples were screened for only IgM class antibodies by ELISA.Results: Net prevalence of IgM antibodies to human parvovirus B19 in our study was 7.53% and prevalence of IgG antibodies was 27.96%. Dual positivity (IgG and IgM) was 2.40%. Conclusion:The seroprevalence of human parvovirus B19 among blood donor population in our study is high, and poses an adverse transfusion risk especially in high-risk group of patients who have no detectable antibodies to B19. Studies with large sample size are needed to validate these results.ª 2012, Armed Forces Medical Services (AFMS). All rights reserved.

show abstract

Parvovirus B19 infections in state of Rio de Janeiro, Brasil: 526 sera analyzed by IgM-enzyme-linked immunosorbent assay and polymerase chain reaction

Abstract: In this study were analyzed 526 sera; the patients aged from two days to 65 years old presenting exanthema, which was the most frequent symptom observed, besides fever, adenomegaly, and arthralgia. These sera were negative by enzyme-linked immunosorbent assay (IgM-ELISA)

Cited by 7 publications

References 29 publications

Identification of human parvovirus B19 among measles and rubella suspected patients from Cuba

Identification of human parvovirus B19 among measles and rubella suspected patients from Cuba

Infection and immunity for human parvovirus B19 in patients with febrile exanthema

Seroprevalence of human parvovirus B19 in healthy blood donors

Contact Info

Product

Resources

About